Search | Clinical Trials Finder

Conditions: Diabetes
Interventions: Ramipril, Candesartan cilexetil, Allopurinol; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Conditions: Heart Failure
Interventions: Placebo, Omecamtiv mecarbil; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more

Conditions: Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Non-compaction Cardiomyopathy
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Conditions: Mitral Regurgitation
Interventions: metoprolol succinate (Toprol XL), Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Myocardial Ischemia, Left Ventricular Systolic Dysfunction, Elevated Cardiac Enzymes
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions: Levosimendan, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more

Conditions: Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions: Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 254
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more

Conditions: HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
Interventions: Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Heart Failure, Congestive
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more

Conditions: Pediatric Heart Failure
Interventions: LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 18 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Conditions: Peripartum Cardiomyopathy, Diastolic Dysfunction
Interventions: A clinical Transthoracic echocardiogram; Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cardiomyopathy Due to Drug, Heart Failure, Systolic
Interventions: Lisinopril, Placebo Oral Tablet; Drug
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders, Obesity, Hypertension, Coronary Artery Vasospasm, Right Ventricular Overload, Left Ventricular Function Systolic Dysfunction, Ventricular Hypertrophy
Interventions: Clinically prescribed CPAP therapy; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Left Ventricular Dysfunction
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Heart Failure, Asymptomatic Systolic Dysfunction
Interventions: Nesiritide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions: Not listed
Lead sponsor: Seattle Institute for Cardiac Research; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Acute Myocardial Infarction
Interventions: LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5,669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 81
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more

Conditions: Heart Failure (HF)
Interventions: Ivabradine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Wilmington, Delaware • Detroit, Michigan • Buffalo, New York

Conditions: Left Ventricular Systolic Dysfunction
Interventions: AI-ECG; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 102
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 99 more

Search by objective public record fields.

Impact of Diabetes on Left Ventricular Remodeling

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Pediatric Cardiomyopathy Mutation Analysis

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

The Acute Cardiovascular Effects of Marathon Running Using Magnetic Resonance Imaging

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Cardiac Safety Study in Patients With HER2 + Breast Cancer

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function

SCD-HeFT 10 Year Follow-up

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

The SMART-LV Pilot Study

The Product Surveillance Registry REVERSE Post Approval Study